as declared in news-medical
Researchers identify, validate three distinct molecular subtypes of prostate cancer
Researchers identify, validate three distinct molecular subtypes of prostate cancer
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).Findings represent a step toward the implementation of personalized medicine in prostate cancer care.To diagnose and determine treatment for prostate cancer, clinicians consider many factors, including a digital rectal exam, the prostate specific antigen (PSA) level in a patient's blood and prostate tumor biopsy results.Molecular subtyping of tumor cells allows oncologists to individualize care and tailor treatment based on the actual biology of each patient's individual disease.
in the same way medicalxpress
New findings on prostate cancer screening
New findings on prostate cancer screening
Credit: HealthNewsReview The prostate-specific antigen test for prostate cancer was developed in the 1990s, quickly followed by an explosion of PSA screening for the disease and a further explosion of treatment.Treatment consists of either radiation or surgical removal of the prostate.The treatments have hard-to-live-with side effects such as urinary and bowel incontinence and loss of sexual function.Yet the disease itself is often not particularly life-threatening.
additionally livemint
Understanding prostate cancer
Understanding prostate cancer
It's Prostate Cancer Awareness month.This cancer is common yet, "unfortunately, most people don't know that it is easily preventable," says P.K.Julka, director of the Max Institute of Cancer Care in New Delhi.Prostate cancer is the second most common cancer among men after lung cancer, according to the 2012 figures released by Globocan, a cancer surveillance database managed by the International Association of Cancer Registries.
No comments:
Post a Comment